Dr Adam Kittai, MD, FACS

Adam Kittai, an oncologist practicing in Columbus, OH. He currently practices at James Cancer Hospital Solove Research Institute and is affiliated with Ohio State University. In 2012 he graduated from Tel Aviv University’s Sackler Faculty of Medicine.

Dr. Kittai discusses how second generation BTK inhibitors are altering treatment decisions among CLL patients, and provides key advice to individuals considering clinical trial participation.

Early Life and Education

Dr. Adam Kittai brings over 10 years of healthcare experience and graduated from Tel Aviv University/ SACKLER FACULTY OF MEDICINE in 2012. Currently practicing at Hematology Specialists in Columbus, OH as well as participating in clinical research to keep abreast of any advances that might benefit his patients, Dr. Kittai has earned multiple industry accolades including Best Physician.

Though I found the book slow and dull, I enjoyed that it took place during a pre-cell phone/pre-Internet era. This allowed Eva’s loneliness to ring true while showing Deacon off as someone not ready for relationships just because Lavona told him so.

Professional Career

Adam Kittyai is a Hematology/Oncology Specialist located in Columbus, OH. After receiving his degree from Tel Aviv University / Sackler Faculty of Medicine in 2012, he currently practices at Select Specialty Hosp-Columbus while also being affiliated with James Cancer Hospital Solove Research Institute and accepting multiple insurance plans – being board certified in Hematology as a result of this.

At MediFind’s database, he is recognized as an expert for seven conditions he co-wrote 43 medical articles on and participated in 2 clinical trials during his career.

He has received payments for meals, travel compensation and consulting work. In addition to that he is a member of the American Society of Hematology.

Personal Life

Dr. Adam Kittai has over 10 years of experience in medicine, having graduated from TEL AVIV UNIVERSITY/ SACKLER FACULTY OF MEDICINE. Currently practicing at Select Specialty Hosp-Columbus with multiple insurance plans accepted and board-certification in Hematology.

He is highly-rated by patients and considered an authority in various conditions. Additionally, he is affiliated with James Cancer Hospital Solove Research Institute and Ohio State University Comprehensive Cancer Center.

He has received personal fees from Bristol-Myers Squibb outside his submitted work as well as grants from Magenta Therapeutics, Incyte Pharmaceuticals and CareDx. He has also received compensation for consulting and advisory boards at Novartis, Kite CRISPR Therapeutics Takeda Juno as well as compensation for publishing two peer reviewed papers.